Phaseline

Targets › NS3

NS3: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 4; Infectious disease; next expected readout Jul 2029.

Open in Phaseline: the race on NS3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Kirby InstitutePibrentasvir
Nonstructural protein 5A inhibitor
NS3, NS5APhase 4Hepatitis CJul 2029

Conditions

Hepatitis C (1)

Modalities

small molecule (1)

Companies

Kirby Institute (1)

Related targets

NS5A (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.